PhaseBio Pharmaceuticals Inc

$ Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000116924521000035 Filed on May 13, 2021

Income Statement

Concept	2021 Q1	2020 Q1

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.00M	$59.40M
YoY Change	29.63%	14.45%
Cash & Equivalents	$77.00M	$59.40M
Short-Term Investments
Other Short-Term Assets	$11.20M	$12.20M
YoY Change	-8.2%	713.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables		$896.0K
Total Short-Term Assets	$88.16M	$72.54M
YoY Change	21.53%	34.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.79M	$2.637M
YoY Change	309.25%	593.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$57.00K	$32.00K
YoY Change	78.13%	0.0%
Total Long-Term Assets	$12.66M	$4.317M
YoY Change	193.35%	86.8%
TOTAL ASSETS
Total Short-Term Assets	$88.16M	$72.54M
Total Long-Term Assets	$12.66M	$4.317M
Total Assets	$100.8M	$76.86M
YoY Change	31.18%	36.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.898M	$1.918M
YoY Change	207.51%	-8.67%
Accrued Expenses	$5.400M	$1.900M
YoY Change	184.21%	46.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.370M	$3.686M
YoY Change	45.69%	821.5%
Total Short-Term Liabilities	$16.67M	$7.495M
YoY Change	122.39%	97.24%
LONG-TERM LIABILITIES
Long-Term Debt	$5.425M	$11.06M
YoY Change	-50.94%	61.64%
Other Long-Term Liabilities	$629.0K	$295.0K
YoY Change	113.22%	-82.65%
Total Long-Term Liabilities	$6.054M	$11.35M
YoY Change	-46.67%	65.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.67M	$7.495M
Total Long-Term Liabilities	$6.054M	$11.35M
Total Liabilities	$92.41M	$23.37M
YoY Change	295.39%	89.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$288.1M	-$177.1M
YoY Change	62.71%	35.99%
Common Stock	$48.00K	$29.00K
YoY Change	65.52%	16.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$24.00K	$24.00K
YoY Change	0.0%	0.0%
Treasury Stock Shares	29.97K shares	29.97K shares
Shareholders Equity	$8.411M	$53.49M
YoY Change
Total Liabilities & Shareholders Equity	$100.8M	$76.86M
YoY Change	31.18%	36.31%

Cashflow Statement

Concept	2021 Q1	2020 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	PhaseBio Pharmaceuticals Inc
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001169245
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	us-gaap:GrantMember
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-38697
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	03-0375697
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Great Valley Parkway
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19355
CY2021Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 30
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Malvern
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2021Q1	dei	City Area Code CityAreaCode	610
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	981-6500
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2021Q1	dei	Trading Symbol TradingSymbol	PHAS
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47952033	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	76963000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28122000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11194000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12027000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	88157000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	40149000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10792000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8224000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1815000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1927000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	57000	USD
CY2021Q1	us-gaap	Assets Assets	100821000	USD
CY2020Q4	us-gaap	Assets Assets	50357000	USD
CY2021Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	5370000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5355000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5898000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3674000	USD
CY2021Q1	phas	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5400000	USD
CY2020Q4	phas	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5931000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	16668000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14960000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5425000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	6773000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1428000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1548000	USD
CY2021Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	68260000	USD
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	51719000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	629000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	559000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	92410000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	75559000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47982000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47952033	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	29471854	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	29441887	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	48000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	29000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	29967	shares
CY2021Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	29967	shares
CY2021Q1	us-gaap	Treasury Stock Value TreasuryStockValue	24000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	24000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	296468000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	235516000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288081000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-260723000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	8411000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-25202000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100821000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	50357000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	320000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22320000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11449000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3327000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3159000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	25647000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	14608000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25647000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14288000	USD
CY2021Q1	phas	Gain Loss From Remeasurement Of Derivative Liability GainLossFromRemeasurementOfDerivativeLiability	-1426000	USD
CY2020Q1	phas	Gain Loss From Remeasurement Of Derivative Liability GainLossFromRemeasurementOfDerivativeLiability	-454000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	211000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	285000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	378000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1711000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-617000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-27358000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-14905000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.52
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	31282662	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28773274	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-25202000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	60084000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	217000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	670000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-27358000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	8411000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	59978000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	7925000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	471000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-14905000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	53486000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-27358000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-14905000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	474000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	670000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	471000	USD
CY2021Q1	phas	Gain Loss From Remeasurement Of Derivative Liability GainLossFromRemeasurementOfDerivativeLiability	-1426000	USD
CY2020Q1	phas	Gain Loss From Remeasurement Of Derivative Liability GainLossFromRemeasurementOfDerivativeLiability	-454000	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	93000	USD
CY2020Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	132000	USD
CY2021Q1	phas	Noncashor Part Noncash Researchand Development Expense NoncashorPartNoncashResearchandDevelopmentExpense	11798000	USD
CY2020Q1	phas	Noncashor Part Noncash Researchand Development Expense NoncashorPartNoncashResearchandDevelopmentExpense	557000	USD
CY2021Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2020Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	100000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	USD
CY2020Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-337000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-965000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9602000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2199000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-712000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-467000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-713000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10200000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23827000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	558000	USD
CY2021Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	100000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-133000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-658000	USD
CY2021Q1	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	0	USD
CY2020Q1	us-gaap	Payments For Proceeds From Derivative Instrument Financing Activities PaymentsForProceedsFromDerivativeInstrumentFinancingActivities	-10000000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	60536000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	116000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1364000	USD
CY2020Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59174000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9901000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48841000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14584000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28122000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	74025000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76963000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59441000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	192000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	246000	USD
CY2021Q1	phas	Issuanceof Stockand Warrantsfor Derivative Instruments IssuanceofStockandWarrantsforDerivativeInstruments	0	USD
CY2020Q1	phas	Issuanceof Stockand Warrantsfor Derivative Instruments IssuanceofStockandWarrantsforDerivativeInstruments	7925000	USD
CY2021Q1	phas	Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	370000	USD
CY2020Q1	phas	Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	45000	USD
CY2021Q1	phas	Capital Expenditures Incurred But Not Yet Paid Incurring Development Derivative Liability CapitalExpendituresIncurredButNotYetPaidIncurringDevelopmentDerivativeLiability	3317000	USD
CY2020Q1	phas	Capital Expenditures Incurred But Not Yet Paid Incurring Development Derivative Liability CapitalExpendituresIncurredButNotYetPaidIncurringDevelopmentDerivativeLiability	0	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	969000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1031000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-288100000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77000000.0	USD
CY2021Q1	phas	Working Capital WorkingCapital	71500000	USD
CY2021Q1	phas	Aggregate Offering Price Of Common Stock Preferred Stock Debt Securities And Warrants AggregateOfferingPriceOfCommonStockPreferredStockDebtSecuritiesAndWarrants	200000000.0	USD
CY2021Q1	phas	Proceeds From Issuance Of Common Stock Excluding Underwriting Discounts Commissions And Other Offering Costs ProceedsFromIssuanceOfCommonStockExcludingUnderwritingDiscountsCommissionsAndOtherOfferingCosts	60100000	USD
CY2021Q1	phas	Aggregate Offering Price Of Common Stock Preferred Stock Debt Securities And Warrants Remaining AggregateOfferingPriceOfCommonStockPreferredStockDebtSecuritiesAndWarrantsRemaining	132600000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed financial statements and accompanying notes. The most significant estimates in the Company’s condensed financial statements relate to the valuation of the development derivative liability and the clinical trial accruals. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span></div>
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt;text-align:justify"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:54pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains certain deposit accounts and money market funds in federally insured financial institutions in excess of federally insured limits. The Company could experience losses on the money market funds in the future.</span></div>
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7107840	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5973505	shares
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13392000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10350000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2600000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2126000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10792000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8224000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	500000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	100000	USD
CY2021Q1	phas	Accrued Clinical And Related Costs Current AccruedClinicalAndRelatedCostsCurrent	2967000	USD
CY2020Q4	phas	Accrued Clinical And Related Costs Current AccruedClinicalAndRelatedCostsCurrent	2753000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1223000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2260000	USD
CY2021Q1	us-gaap	Interest Payable Current InterestPayableCurrent	61000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	69000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	468000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	459000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	681000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	390000	USD
CY2021Q1	phas	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5400000	USD
CY2020Q4	phas	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5931000	USD
CY2010Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y4M24D
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	424000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	555000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	419000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	279000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	283000	USD
CY2021Q1	phas	Lessee Operating Lease Liability To Be Paid Due After Year Four LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour	215000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2175000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	279000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1896000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	200000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	100000	USD
CY2021Q1	phas	Aggregate Offering Price Of Common Stock Preferred Stock Debt Securities And Warrants Remaining AggregateOfferingPriceOfCommonStockPreferredStockDebtSecuritiesAndWarrantsRemaining	132600000	USD
CY2019Q4	phas	Sale Of Stock Stock Debt And Warrants Amount Authorized SaleOfStockStockDebtAndWarrantsAmountAuthorized	200000000.0	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	670000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	471000	USD
CY2021Q1	us-gaap	Purchase Obligation Due In Second And Third Year PurchaseObligationDueInSecondAndThirdYear	14000000.0	USD
CY2021Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	37000000.0	USD
CY2021Q1	phas	Purchase Obligation To Be Paid Year Five Through Eleven PurchaseObligationToBePaidYearFiveThroughEleven	48000000.0	USD

Files In Submission

Name	View Source	Status
0001169245-21-000035-index-headers.html	Edgar Link	pending
0001169245-21-000035-index.html	Edgar Link	pending
0001169245-21-000035.txt	Edgar Link	pending
0001169245-21-000035-xbrl.zip	Edgar Link	pending
ex-321xphas10xq2021q1.htm	Edgar Link	pending
ex-322xphas10xq2021q1.htm	Edgar Link	pending
ex102-phas10xq2021q1.htm	Edgar Link	pending
ex311-phas10xq2021q1.htm	Edgar Link	pending
ex312-phas10xq2021q1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
phas-20210331.htm	Edgar Link	pending
phas-20210331.xsd	Edgar Link	pending
phas-20210331_cal.xml	Edgar Link	unprocessable
phas-20210331_def.xml	Edgar Link	unprocessable
phas-20210331_htm.xml	Edgar Link	completed
phas-20210331_lab.xml	Edgar Link	unprocessable
phas-20210331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

PhaseBio Pharmaceuticals Inc

2021 Q1 Form 10-Q Financial Statement

#000116924521000035 Filed on May 13, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission